BioCentury
ARTICLE | Product Development

Next-generation checkpoints take another hit as Jounce stops enrollment in ICOS agonist trial

November 2, 2020 9:48 PM UTC

Jounce’s strategy to re-focus its anti-ICOS mAb program on patients with ICOS-high T cells hit a roadblock on Monday when the company said it was stopping enrollment in a Phase II study. 

Jounce Therapeutics Inc. (NASDAQ:JNCE) reported that the combination of vopratelimab plus anti-CTLA-4 mAb Yervoy ipilimumab did not meet pre-specified interim criteria for continued enrollment. ...

BCIQ Company Profiles

Jounce Therapeutics Inc.